Expert Interview

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Discussing Psychiatric Perspectives on Bristol Myers Squibbs' Cobenfy® (KarXT) for Alzheimer’s Psychosis

Ticker(s): BMY

Who's the expert?

Institution: UC Irvine

Assistant Professor of Psychiatry at UC Irvine Medical Center.
Currently manages 110 patients with MDD and 20 patients with Alzheimer's psychosis; Active prescriber of Cobenfy for Schizophrenia
Research Focus: Antidepressant withdrawal and psychopharmacology

Interview Questions

Q1.

How many patients do you manage with Alzheimer’s psychosis?

Added By: lilly_admin

Q2.

On a scale of 1 to 10 (with 10 being ecstatic), how excited are you for Cobenfy® (KarXT) as a potential treatment for Alzheimer’s Psychosis?

Added By: lilly_admin

Q3.

What has been your experience prescribing Cobenfy for schizophrenia patients?

Added By: ben_admin

Q4.

Do you think Cobenfy will be efficacious for Alzheimer's psychosis patients?

Added By: ben_admin

Are You Interested In These Questions?

Yes! Sign me up for FREE
so I can learn more Yes.
LOGIN!

Click Here to Access
This Project

Slingshot Insights Explained

JOIN FOR FREE TODAY

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

Click Here to Access
This Project

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.